Heat Biologics Inc (HTBX) Expected to Announce Quarterly Sales of $1.50 Million

Share on StockTwits

Analysts expect that Heat Biologics Inc (NASDAQ:HTBX) will report sales of $1.50 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Heat Biologics’ earnings. The highest sales estimate is $1.80 million and the lowest is $1.20 million. The business is expected to issue its next earnings report on Thursday, February 21st.

According to Zacks, analysts expect that Heat Biologics will report full-year sales of $5.22 million for the current year, with estimates ranging from $4.90 million to $5.54 million. For the next financial year, analysts forecast that the company will post sales of $4.95 million, with estimates ranging from $4.80 million to $5.10 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Heat Biologics.

Heat Biologics (NASDAQ:HTBX) last posted its quarterly earnings data on Thursday, November 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.05. The business had revenue of $1.84 million during the quarter, compared to analysts’ expectations of $1.50 million. Heat Biologics had a negative net margin of 331.02% and a negative return on equity of 94.53%.

HTBX has been the subject of several recent analyst reports. HC Wainwright set a $6.00 price objective on shares of Heat Biologics and gave the company a “buy” rating in a report on Friday, November 16th. ValuEngine upgraded shares of Heat Biologics from a “hold” rating to a “buy” rating in a report on Thursday, November 1st.

Heat Biologics stock opened at $1.25 on Friday. Heat Biologics has a 12-month low of $0.95 and a 12-month high of $4.50.

A number of large investors have recently modified their holdings of HTBX. Northern Trust Corp bought a new stake in Heat Biologics during the second quarter worth approximately $111,000. Vanguard Group Inc boosted its holdings in Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc now owns 798,561 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 136,256 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in Heat Biologics by 20.6% during the third quarter. Vanguard Group Inc. now owns 798,561 shares of the biopharmaceutical company’s stock worth $1,597,000 after buying an additional 136,256 shares in the last quarter. Hedge funds and other institutional investors own 4.46% of the company’s stock.

About Heat Biologics

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Recommended Story: How are institutional investors different from individual investors?

Get a free copy of the Zacks research report on Heat Biologics (HTBX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Village Farms International  Trading 20.4% Higher
Village Farms International Trading 20.4% Higher
Enablence Technologies  Trading Down 16.7%
Enablence Technologies Trading Down 16.7%
Q4 2019 EPS Estimates for Citizens Financial Group Inc  Lowered by Wedbush
Q4 2019 EPS Estimates for Citizens Financial Group Inc Lowered by Wedbush
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
Wynn Resorts, Limited Expected to Post FY2020 Earnings of $7.70 Per Share
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
UBS Group Reaffirms Buy Rating for Puma AG Rudolf Dassler Sport
Trevali Mining  Price Target Lowered to C$0.60 at National Bank Financial
Trevali Mining Price Target Lowered to C$0.60 at National Bank Financial


Leave a Reply

 
© 2006-2019 Zolmax.